LGVN
Longeveron Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
0.85
▲ 0.02 (2.63%)
MARKET · —
Price
Open
0.86
Prev close
0.83
Day high
0.87
Day low
0.82
Volume
768.60K
Market cap
$26.94M
P/E (TTM)
—
52W range
0.48 – 1.23
Trailing performance
Returnvs SPY
1W
+14.19%
+15.6%
1M
+39.21%
+35.5%
3M
+17.20%
+14.1%
6M
+46.96%
+35.9%
YTD
+67.00%
+54.7%
1Y
+5.63%
-14.4%
3Y
-97.05%
-171.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$26.94M
Enterprise value$17.44M
Revenue (TTM)$1.19M
Gross profit$828.00K
EBITDA$-22.44M
Net income$-23.47M
EPS (TTM)$-1.00
Free cash flow$-11.60M
Total cash$10.08M
Total debt$581.00K
Book value / share$0.33
Shares outstanding30.43M
Float27.08M
Short % of float5.34%
Dividend yield—
Beta (5Y)-0.25
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.55
PEG ratio—
Price / sales—
Price / book2.58
EV / revenue14.69
EV / EBITDA-0.78
Gross margin69.76%
Operating margin-2150.17%
Profit margin0.00%
Return on equity-203.61%
Return on assets-90.95%
Debt / equity5.59
Current ratio2.63
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $1.20M | $2.39M | $709.00K | $1.22M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$22.70M | -$15.97M | -$21.41M | -$18.84M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$22.70M | -$15.97M | -$21.41M | -$18.84M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.19 | -0.19 | 0.0% |
| Mar 2026 | -0.17 | -0.19 | -10.1% |
| Dec 2025 | -0.37 | -0.22 | +40.0% |
| Sep 2025 | -0.26 | -0.39 | -51.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.17 | 4 | $411.00K | +200.0% |
| Next quarter | -0.16 | 4 | $436.50K | +19.6% |
| Current year | -0.72 | 4 | $1.54M | +28.4% |
| Next year | -0.47 | 4 | $6.53M | +324.4% |
Analyst targets & ownership
Mean target$7.15
High target$10.45
Low target$3.00
Implied upside741.18%
Analyst count3
ConsensusBUY
Strong buy / Buy0 / 2
Hold1
Sell / Strong sell0 / 0
Held by insiders9.57%
Held by institutions20.55%
Institutions holding41
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.05M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| May 1, 26 | WILLARD STEPHEN H Chief Executive Officer |
STOCK | 500.00K | $0 | Direct |
| May 1, 26 | LEHR PAUL T General Counsel |
STOCK | 250.00K | $0 | Direct |
| May 1, 26 | AGAFONOVA NATALIYA Officer |
STOCK | 250.00K | $0 | Direct |
| May 1, 26 | LOCKLEAR LISA Chief Financial Officer |
STOCK | 250.00K | $0 | Direct |
| May 1, 26 | BLASS DEVIN Officer |
STOCK | 250.00K | $0 | Direct |
| Mar 2, 26 | WILLARD STEPHEN H Chief Executive Officer |
STOCK | 400.00K | $0 | Direct |
| Oct 1, 25 | PALETTA GEORGE A JR. Director |
STOCK | 34.00K | $0 | Direct |
| Sep 4, 25 | POWELL JAMES NATHANIEL Chief Executive Officer |
STOCK | 50.00K | $0 | Direct |
| Aug 11, 25 | BALUCH KHOSO Director |
BUY | 11.77K | $8.18K | Direct |
| Aug 11, 25 | LOCKLEAR LISA Chief Financial Officer |
BUY | 11.77K | $8.18K | Direct |
| Jul 15, 25 | BALUCH KHOSO Director |
STOCK | 17.00K | $0 | Direct |
| Jul 15, 25 | SOFFER ROCK J Director |
STOCK | 17.00K | $0 | Direct |
| Jul 15, 25 | LEHR PAUL T General Counsel |
STOCK | 102.00K | $0 | Direct |
| Jul 15, 25 | UNGARO URSULA Director |
STOCK | 17.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AGAFONOVA NATALIYA |
Officer | 453.42K | Stock Award(Grant) |
BALUCH KHOSO |
Director | 52.52K | Purchase |
BLASS DEVIN |
Officer | 441.54K | Stock Award(Grant) |
HARE JOSHUA M |
Officer, Director and Beneficial Owner | 721.80K | Sale |
HASHAD MOHAMED WA'EL AHMED |
Chief Executive Officer | 420.90K | Stock Award(Grant) |
LEHR PAUL T |
General Counsel | 588.57K | Stock Award(Grant) |
LOCKLEAR LISA |
Chief Financial Officer | 465.69K | Stock Award(Grant) |
POWELL JAMES NATHANIEL |
Chief Executive Officer | 130.45K | Stock Award(Grant) |
SOFFER ROCK J |
Director | 226.03K | Stock Award(Grant) |
WILLARD STEPHEN H |
Chief Executive Officer | 789.73K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
0.77
+10.17% from price
SMA 20
0.73
+15.44% from price
SMA 50
0.71
+19.17% from price
SMA 100
0.80
+5.97% from price
SMA 200
0.72
+17.06% from price
EMA 12
0.78
+9.52% from price
EMA 26
0.74
+15.14% from price
EMA 50
0.73
+16.16% from price
RSI (14)
64.0
Neutral
MACD (12,26,9)
0.04
Hist 0.01
ATR (14)
0.07
8.75% of price
Realised vol 30D
74.7%
Annualised
Bollinger upper
0.87
20, 2σ
Bollinger lower
0.59
20, 2σ
50 / 200 cross
Death
0.71 vs 0.72
Trend bias
Above 200
+17.06%
Risk profile
Beta vs SPY
1.03
More volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
74.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-48.7%
Peak to trough
Max drawdown 5Y
-99.9%
Peak to trough
ATR 14
0.07
8.75% of price
Beta (reported)
-0.25
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Longeveron (LGVN) Q2 2026 Earnings Call Transcript
Motley Fool · 3d ago
Longeveron Appoints Nirav Jhaveri As CFO
MT Newswires · 3d ago
Longeveron Appoints Nirav Jhaveri as Chief Financial Officer
GlobeNewswire · 3d ago
LGVN at a Major Inflection Point
Zacks Small Cap Research · 9d ago
Longeveron Inc. Q2 2026 Earnings Call Summary
Moby · 10d ago
Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update
GlobeNewswire · 10d ago
Earnings To Watch: Longeveron Inc (LGVN) Q2 2026 -- GF Value Sees 58% Downside
GuruFocus.com · 11d ago
Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition
GlobeNewswire · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.